Skip to content

Ontologically Challenging Psychedelic Experiences: Considerations for Managing Associated Distress.

Eirini K. Argyri, Jules Evans

Current Topics in Behavioral Neurosciences 2026 DOI: 10.1007/7854_2025_609 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Review Qualitative Peer reviewed
Topics End-of-life distress
Keywords Ontological shock Psychedelic harm reduction Psychedelic integration
Citations 3
Key findings Ontologically challenging psychedelic experiences (OCPEs) can cause lasting existential distress and instability, but when adequately resourced, they can also be a valued part of therapeutic growth.

Abstract

Psychedelic substances have been increasingly recognised for their potential in treating various mental health conditions, yet they can also induce what we call ontologically challenging psychedelic experiences (OCPEs), a concept developed in our research to describe experiences that profoundly disrupt an individual's sense of self, reality, and existence. We present OCPEs not as a diagnostic category but as a phenomenological and harm reduction perspective on certain destabilising psychedelic experiences.While some individuals integrate OCPEs with ease, others struggle with ontological instability, existential distress, and impairments that persist long after acute effects. Importantly, ontological challenges are not always negative: for many, when they feel adequately resourced, they form part of the therapeutic mechanism and are a valued opportunity for personal development and growth. Drawing on our qualitative studies alongside other psychological research, we examine the phenomenology of OCPEs and their challenging aftermath, as well as strategies that may help facilitate recovery and integration. Grounding techniques, cognitive (re)framing, and supportive structures are discussed as potentially beneficial approaches and resources.Finally, we outline ethical and practical implications for clinical and harm reduction practice. We highlight the limits of informed consent in psychedelic therapy and argue for the value of preparation and post-experience support that is attuned to ontological disruptions. As empirical evidence remains limited, further research is needed to refine best practices. The development of an ethically responsible approach, informed by the phenomenology of OCPEs, can help maximise benefits of psychedelic substances while minimising long-term harm.

Comparable studies

Other narrative reviews on end-of-life distress, most cited first.

Study Year Design Participants
Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-Assisted Therapy in the Context of Serious Illness. Palliative care clinicians and patients 2022 Review
The Potential of Psychedelics for End of Life and Palliative Care. Patients with life-threatening diagnoses 2022 Review
Psilocybin in Palliative Care: An Update. Palliative care patients 2023 Review
Psychedelic medicines for end-of-life care: Pipeline clinical trial review 2022. People with terminal illnesses experiencing depression, anxiety, or existential distress 2023 Scoping review n = 25
Psilocybin-assisted psychotherapy for existential distress: practical considerations for therapeutic application—a review 2024 Narrative review

Citations in the library

Explore topics